The Trump administration Friday released a long-awaited rebate rule, and it’s a mixed bag for community pharmacy.
In a statement, NCPA said, "On one hand, the rule tries to address the complexity and lack of transparency that allows PBMs to game the system. They use rebates to hide the true cost of prescription drugs, and that makes it impossible for policymakers and consumers to know how much they’re really paying, or why. On the other hand, the rule fails to address pharmacy DIR fees, which is a form of extortion that is killing small-business, independent pharmacies.”
NCPA will analyze the rule in detail and will report further early next week.